CytoDyn Inc. (CYDY)
USD 0.23
(-1.61%)
USD 0.23
(-1.61%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -18.05 Million USD | 55.5% |
| 2023 | -40.57 Million USD | 43.58% |
| 2022 | -71.91 Million USD | 31.25% |
| 2021 | -104.59 Million USD | -40.12% |
| 2020 | -74.64 Million USD | -33.65% |
| 2019 | -55.85 Million USD | -21.63% |
| 2018 | -45.91 Million USD | -68.01% |
| 2017 | -27.33 Million USD | -29.07% |
| 2016 | -21.17 Million USD | -8.06% |
| 2015 | -19.59 Million USD | -141.55% |
| 2014 | -8.11 Million USD | -1.49% |
| 2013 | -7.99 Million USD | -7.21% |
| 2012 | -7.45 Million USD | -101.6% |
| 2011 | -3.69 Million USD | -0.67% |
| 2010 | -3.67 Million USD | -96.52% |
| 2009 | -1.86 Million USD | -73.28% |
| 2008 | -1.07 Million USD | 56.24% |
| 2007 | -2.46 Million USD | -108.91% |
| 2006 | -1.18 Million USD | -52.22% |
| 2005 | -775.18 Thousand USD | -116.86% |
| 2004 | -357.45 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.39 Million USD | 26.32% |
| 2024 FY | -18.05 Million USD | 55.5% |
| 2024 Q4 | -6.63 Million USD | -94.32% |
| 2024 Q1 | -4.61 Million USD | -22.01% |
| 2024 Q3 | -3.41 Million USD | -0.47% |
| 2023 Q1 | -9.71 Million USD | 87.71% |
| 2023 FY | -40.57 Million USD | 43.58% |
| 2023 Q3 | -3.92 Million USD | 83.07% |
| 2023 Q4 | -3.78 Million USD | 3.6% |
| 2023 Q2 | -23.16 Million USD | -138.5% |
| 2022 Q1 | -21.63 Million USD | 8.46% |
| 2022 FY | -71.91 Million USD | 31.25% |
| 2022 Q4 | -79.04 Million USD | -307.53% |
| 2022 Q3 | -19.39 Million USD | 23.4% |
| 2022 Q2 | -25.32 Million USD | -17.03% |
| 2021 Q4 | -23.63 Million USD | 23.22% |
| 2021 Q1 | -25.56 Million USD | 8.09% |
| 2021 Q2 | -24.5 Million USD | 4.17% |
| 2021 FY | -104.59 Million USD | -40.12% |
| 2021 Q3 | -30.78 Million USD | -25.64% |
| 2020 Q1 | -12.63 Million USD | 8.49% |
| 2020 Q3 | -22.07 Million USD | -82.12% |
| 2020 FY | -74.64 Million USD | -33.65% |
| 2020 Q4 | -27.81 Million USD | -26.02% |
| 2020 Q2 | -12.12 Million USD | 4.05% |
| 2019 Q2 | -15.68 Million USD | -16.3% |
| 2019 Q1 | -13.48 Million USD | -20.47% |
| 2019 Q3 | -12.87 Million USD | 17.95% |
| 2019 Q4 | -13.8 Million USD | -7.25% |
| 2019 FY | -55.85 Million USD | -21.63% |
| 2018 Q2 | -10.77 Million USD | -9.87% |
| 2018 FY | -45.91 Million USD | -68.01% |
| 2018 Q1 | -9.8 Million USD | -25.74% |
| 2018 Q3 | -14.14 Million USD | -31.23% |
| 2018 Q4 | -11.19 Million USD | 20.82% |
| 2017 FY | -27.33 Million USD | -29.07% |
| 2017 Q2 | -6.15 Million USD | -14.89% |
| 2017 Q3 | -8.01 Million USD | -30.23% |
| 2017 Q4 | -7.79 Million USD | 2.71% |
| 2017 Q1 | -5.35 Million USD | 18.51% |
| 2016 Q1 | -6.65 Million USD | 35.73% |
| 2016 FY | -21.17 Million USD | -8.06% |
| 2016 Q2 | -2.89 Million USD | 56.53% |
| 2016 Q4 | -6.57 Million USD | -30.23% |
| 2016 Q3 | -5.04 Million USD | -74.48% |
| 2015 Q4 | -10.35 Million USD | -214.59% |
| 2015 Q1 | -2.95 Million USD | -12.12% |
| 2015 Q3 | -3.29 Million USD | -10.05% |
| 2015 FY | -19.59 Million USD | -141.55% |
| 2015 Q2 | -2.99 Million USD | -1.26% |
| 2014 Q1 | -1 Million USD | 47.73% |
| 2014 Q4 | -2.63 Million USD | 8.36% |
| 2014 Q3 | -2.87 Million USD | -79.62% |
| 2014 FY | -8.11 Million USD | -1.49% |
| 2014 Q2 | -1.6 Million USD | -59.94% |
| 2013 Q4 | -1.91 Million USD | -18.0% |
| 2013 FY | -7.99 Million USD | -7.21% |
| 2013 Q3 | -1.62 Million USD | 1.27% |
| 2013 Q2 | -1.64 Million USD | 41.56% |
| 2013 Q1 | -2.81 Million USD | 17.05% |
| 2012 Q1 | -1.15 Million USD | -5.28% |
| 2012 FY | -7.45 Million USD | -101.6% |
| 2012 Q4 | -3.39 Million USD | -139.61% |
| 2012 Q3 | -1.41 Million USD | 5.15% |
| 2012 Q2 | -1.49 Million USD | -28.76% |
| 2011 FY | -3.69 Million USD | -0.67% |
| 2011 Q2 | -1.05 Million USD | -78.48% |
| 2011 Q3 | -1.06 Million USD | -1.52% |
| 2011 Q4 | -1.1 Million USD | -3.0% |
| 2011 Q1 | -589.66 Thousand USD | 70.46% |
| 2010 Q4 | -1.99 Million USD | -179.82% |
| 2010 Q1 | -275.53 Thousand USD | 30.9% |
| 2010 Q2 | -688.52 Thousand USD | -149.88% |
| 2010 Q3 | -713.34 Thousand USD | -3.61% |
| 2010 FY | -3.67 Million USD | -96.52% |
| 2009 FY | -1.86 Million USD | -73.28% |
| 2009 Q1 | -552.44 Thousand USD | -22.03% |
| 2009 Q3 | -272.15 Thousand USD | 57.86% |
| 2009 Q4 | -398.77 Thousand USD | -46.52% |
| 2009 Q2 | -645.87 Thousand USD | -16.91% |
| 2008 Q2 | -247.48 Thousand USD | -10.29% |
| 2008 Q3 | -154.16 Thousand USD | 37.71% |
| 2008 Q4 | -452.7 Thousand USD | -193.65% |
| 2008 FY | -1.07 Million USD | 56.24% |
| 2008 Q1 | -224.39 Thousand USD | 57.62% |
| 2007 Q4 | -529.52 Thousand USD | 4.03% |
| 2007 FY | -2.46 Million USD | -108.91% |
| 2007 Q2 | -682.07 Thousand USD | -23.61% |
| 2007 Q1 | -551.79 Thousand USD | 28.73% |
| 2007 Q3 | -551.73 Thousand USD | 19.11% |
| 2006 FY | -1.18 Million USD | -52.22% |
| 2006 Q3 | -255.07 Thousand USD | -206.73% |
| 2006 Q2 | -83.16 Thousand USD | -23.12% |
| 2006 Q1 | -67.54 Thousand USD | 14.41% |
| 2006 Q4 | -774.23 Thousand USD | -203.53% |
| 2005 Q2 | -123.32 Thousand USD | -2.18% |
| 2005 Q1 | -120.7 Thousand USD | 28.38% |
| 2005 FY | -775.18 Thousand USD | -116.86% |
| 2005 Q3 | -452.23 Thousand USD | -266.69% |
| 2005 Q4 | -78.91 Thousand USD | 82.55% |
| 2004 Q1 | -1828.00 USD | 0.0% |
| 2004 Q2 | -58.12 Thousand USD | -3079.81% |
| 2004 FY | -357.45 Thousand USD | 0.0% |
| 2004 Q3 | -128.99 Thousand USD | -121.92% |
| 2004 Q4 | -168.52 Thousand USD | -30.64% |
| 2003 Q1 | -3098.00 USD | 0.0% |
| 2003 Q2 | -2118.00 USD | 31.63% |
| 2003 Q3 | -1584.00 USD | 25.21% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1252.223% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -257.975% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -1.182% |
| Nascent Biotech, Inc. | -2.22 Million USD | -709.82% |
| Rebus Holdings, Inc. | -664 Thousand USD | -2619.578% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 122.062% |
| Qrons Inc. | -643.67 Thousand USD | -2705.444% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -4535.367% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 67.468% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -4246.309% |
| Skye Bioscience, Inc. | -13.67 Million USD | -32.082% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 74.845% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 467.42% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -6799.582% |
| SQZ Biotechnologies Company | -75.82 Million USD | 76.185% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -533.501% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1075.614% |
| Mesoblast Limited | -84.14 Million USD | 78.54% |
| Marizyme, Inc. | -34.08 Million USD | 47.023% |
| Genus plc | 6.4 Million USD | 382.156% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 285.354% |
| Pharming Group N.V. | -4.87 Million USD | -270.076% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -809.046% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -1838.843% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -116.263% |
| ContraFect Corporation | -56.88 Million USD | 68.257% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -296.467% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1188.025% |
| IMV Inc. | -38.67 Million USD | 53.304% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -556.454% |
| MultiCell Technologies, Inc. | -722.81 USD | -2498205.225% |
| ONE Bio Corp. | 13.68 Million USD | 231.988% |
| Accustem Sciences Inc. | -3.74 Million USD | -382.007% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 69.388% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -3638.236% |
| Q BioMed Inc. | -3.44 Million USD | -424.086% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 610.113% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -587.264% |
| Biomind Labs Inc. | -1 Million USD | -1688.624% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 67.151% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -522.421% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -171.63% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -868.585% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -60189.797% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -13.789% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -834.384% |
| GB Sciences, Inc. | -1.42 Million USD | -1171.234% |
| Alpha Cognition Inc. | -9.7 Million USD | -86.058% |
| HST Global, Inc. | -140.9 Thousand USD | -12715.545% |
| CSL Limited | 3.7 Billion USD | 100.488% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -1505.29% |
| Halberd Corporation | -75.05 Thousand USD | -23961.292% |
| Enzolytics Inc. | -2.14 Million USD | -740.376% |
| Agentix Corp. | -1.37 Million USD | -1216.415% |
| Resverlogix Corp. | -12.74 Million USD | -41.642% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -469.963% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 95.752% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -1629.693% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -518.542% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -1043.378% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -430.341% |
| AVAX Technologies, Inc. | 6.69 Million USD | 369.809% |
| Zenith Capital Corp. | -8.94 Million USD | -101.923% |
| Genscript Biotech Corporation | -415.79 Million USD | 95.657% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -103556.507% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -635.465% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -10428.86% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -800.758% |
| Kadimastem Ltd | -3.04 Million USD | -493.964% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -1735.064% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -1337.739% |
| BioStem Technologies, Inc. | -7.77 Million USD | -132.139% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -9850.134% |
| LadRx Corporation | -3.82 Million USD | -372.274% |
| Cell Source, Inc. | -4.32 Million USD | -317.493% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2528.721% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2528.721% |
| NovAccess Global Inc. | -2.46 Million USD | -632.053% |
| Affymax, Inc. | -15.04 Million USD | -20.019% |
| Itoco Inc. | -919.14 Thousand USD | -1864.663% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -326.056% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1513.762% |
| Mobile Lads Corp. | -554.55 Thousand USD | -3156.334% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -71644.14% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -8105.273% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -3097.674% |
| SYBLEU INC | -149.18 Thousand USD | -12004.84% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -894.208% |
| International Stem Cell Corporation | -663 Thousand USD | -2623.68% |
| Bioxytran, Inc. | -3.82 Million USD | -372.704% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -34204.711% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -88680.728% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 50.207% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -1016.069% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -2354.083% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -480.456% |
| Neutra Corp. | -229.48 Thousand USD | -7768.89% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -2.959% |
| PureTech Health plc | -146.19 Million USD | 87.648% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 15.975% |
| IXICO plc | -1.43 Million USD | -1156.646% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -90.264% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 85.175% |
| CSL Limited | 3.81 Billion USD | 100.474% |
| Cellectis S.A. | -108.85 Million USD | 83.411% |